her2-mutant

Boehringers HERNEXEOS approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

This press release is not intended for UK and US media.  HERNEXEOS® (zongertinib tablets) has been approved based on an objective…

3 months ago